• Profile
Close

Randomized phase II trial of cisplatin and etoposide in combination with veliparib or placebo for extensive-stage small-cell lung cancer: ECOG-ACRIN 2511 Study

Journal of Clinical Oncology Dec 10, 2018

Owonikoko TK, et al. - Researchers assessed the combination of veliparib with cisplatin and etoposide (CE; CE+V) doublet in untreated, extensive-stage small-cell lung cancer (ES-SCLC). They assessed progression-free survival (PFS) in ES-SCLC patients who were randomly administered four 3-week cycles of CE (75 mg/m2 intravenously on day 1 and 100 mg/m2 on days 1 through 3) along with veliparib (100 mg orally twice per day on days 1 through 7) or placebo (CE+P). These patients were stratified by sex and serum lactate dehydrogenase levels. In patients with ES-SCLC, signal of efficacy was observed following addition of veliparib to frontline chemotherapy and prespecified end point was met.
Go to Original
Only Doctors with an M3 India account can read this article. Sign up for free or login with your existing account.
4 reasons why Doctors love M3 India
  • Exclusive Write-ups & Webinars by KOLs

  • Nonloggedininfinity icon
    Daily Quiz by specialty
  • Nonloggedinlock icon
    Paid Market Research Surveys
  • Case discussions, News & Journals' summaries
Sign-up / Log In
x
M3 app logo
Choose easy access to M3 India from your mobile!


M3 instruc arrow
Add M3 India to your Home screen
Tap  Chrome menu  and select "Add to Home screen" to pin the M3 India App to your Home screen
Okay